Apex BiotechnologyTPE:1733 -0.17%81 ROA % is 8.48% as of Dec. 2025, which is 87% above its 10-year median of 4.53. GuruFocus rates TPE:1733 with a GF Score™ of 81/100 and a GF Value™ of NT$30.08 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Apex Biotechnology ranks better than 90.01% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Apex Biotechnology's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$200 Mil.
Apex Biotechnology's average Total Assets over the quarter that ended in Dec. 2025 was NT$2,363 Mil. Therefore, Apex Biotechnology's annualized ROA % for the quarter that ended in Dec. 2025 was 8.48%.
The historical rank and industry rank for Apex Biotechnology's ROA % or its related term are showing as below:
TPE:1733'
s ROA % Range Over the Past 10 Years
Min: 0.12 Med: 4.53 Max: 7.6
Current: 6.79
During the past 13 years, Apex Biotechnology's highest ROA % was 7.60%. The lowest was 0.12%. And the median was 4.53%.
TPE:1733's ROA % is ranked better than 90.01% of 1411
companies
in the Biotechnology industry
Industry Median: -32.67
vs TPE:1733: 6.79
Apex Biotechnology (TPE:1733) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Apex Biotechnology ROA % Related Terms
Apex Biotechnology ROA % Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Apex Biotechnology's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's ROA % distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Apex Biotechnology (TPE:1733) has a ROA % of 8.48% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Apex Biotechnology and its competitors. This is 87% above median its historical median of 4.53. Over the past decade, Apex Biotechnology's ROA % has ranged from 0.12 to 7.60. According to the industry distribution chart, Apex Biotechnology ranks #141 out of 1411 companies in the Biotechnology industry, placing it in the top 10%.
Is Apex Biotechnology's ROA % too high?
Apex Biotechnology's current ROA % of 8.48% is 87% above median its 10-year median of 4.53. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 7.60. Based on the distribution chart, Apex Biotechnology ranks #141 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Apex Biotechnology has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #141 out of 1411 companies for ROA %. This places Apex Biotechnology in the top 10% of its industry — outperforming the majority of peers. Historically, Apex Biotechnology's own ROA % has ranged from 0.12 to 7.60 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Apex Biotechnology and its competitors. Apex Biotechnology's current ROA % is 8.48%, which is 87% above median its own 10-year median of 4.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.08, compared to a current price of NT$29.90 — trading 0.6% below its estimated fair value. The current ROA % is 8.48%, which is 87% above median its 10-year median of 4.53. Apex Biotechnology's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current ROA % is 8.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be undervalued.
The current stock price of NT$29.90 is trading 0.6% below its estimated GF Value™ of NT$30.08.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
ROA %: 8.48% (87% above median its 10-year median of 4.53)
GF Value™: NT$30.08 vs. price of NT$29.90 (0.6% below fair value)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
81GF Score
Get the complete analysis for TPE:1733
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
